基于结构的发现,强大的CARM1抑制剂用于结直肠癌治疗
Chenyu Liu1, Yang Li1, Zhihao Liu2
1Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, 200062, China.
European journal of medicinal chemistry
|March 9, 2024
概括
研究人员确定了11f化合物是协活性剂相关的阿金氨基甲基转移酶1 (CARM1) 的强有力的抑制剂. 这种化合物在临床前模型中表现出显著的抗癌作用,诱导亡并抑制瘤生长.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 在瘤学瘤学.
背景情况:
- 同活性剂相关的阿尔金因甲基转移酶1 (CARM1) 参与细胞增殖和基因表达.
- 在各种瘤类型中,CARM1经常过度表达,这表明它在癌症发展中的作用.
- 向CARM1为癌症治疗提供了一个潜在的治疗策略.
研究的目的:
- 设计和评估CARM1.1的选择性抑制剂.
- 为了识别具有强大的CARM1抑制活性的化合物.
- 在临床前模型中评估已识别的抑制剂的抗癌潜力.
主要方法:
- 基于之前的CARM1抑制剂支架的结构导向药物设计.
- 在体外酶分析以确定CARM1抑制功效 (IC50).
- 在体外代谢稳定性,分子建模,细胞亡测定和体内抗瘤研究.
主要成果:
- 化合物11f被确定为一种强大的CARM1抑制剂,IC50为9nM.
- 化合物11f证明有效抑制了CARM1的甲基化活性.
- 临床前研究表明,化合物11f诱导癌细胞亡,并对结直肠癌细胞系表现出显著的抗增殖作用.
- 在体内研究证实了化合物11f的抗瘤疗效.
结论:
- 化合物11f是开发选择性CARM1抑制剂的有希望的主要候选者.
- 这些发现支持针对CARM1进行癌症治疗的治疗潜力,特别是针对CARM1相关的恶性瘤.
- 这项研究为进一步开发有效的CARM1向治疗提供了基础.
更多相关视频
06:56A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4
Published on: March 10, 2018
13.7K
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
11.3K
相关概念视频
02:34Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K